Clinical Trial Update: Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating sorafenib with gemcitabine and cisplatin for advanced hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Gemzar (gemcitabine)
• Nexavar (Sorafenib)
• Platinol (cisplatin)

Snippet

Sponsor: Lahey Clinic | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: WITHDRAWN